Patents by Inventor David Paul Gearing
David Paul Gearing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200207861Abstract: A method for inhibition of leukemic stem cells expressing IL-3R? (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: July 19, 2019Publication date: July 2, 2020Applicants: CSL Limited, University Health NetworkInventors: John Edgar DICK, Liqing Jin, Gino Luigi VAIRO, David Paul Gearing, Samantha Jane Busfield
-
Publication number: 20180079818Abstract: A method for inhibition of leukemic stem cells expressing IL-3R? (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: May 5, 2017Publication date: March 22, 2018Applicants: CSL Limited, University Health NetworkInventors: John Edgar Dick, Liqing JIN, Gino Luigi VAIRO, David Paul GEARING, Samantha Jane BUSFIELD
-
Publication number: 20170029515Abstract: A method for inhibition of leukemic stem cells expressing IL-3R? (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: August 10, 2016Publication date: February 2, 2017Applicants: CSL Limited, University Health NetworkInventors: John Edgar Dick, Liqing JIN, Gino Luigi VAIRO, David Paul GEARING, Samantha Jane BUSFIELD
-
Publication number: 20150152185Abstract: A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: November 25, 2014Publication date: June 4, 2015Applicants: CSL LIMITED, UNIVERSITY HEALTH NETWORKInventors: JOHN EDGAR DICK, LIQING JIN, GINO LUIGI VAIRO, DAVID PAUL GEARING, SAMANTHA JANE BUSFIELD
-
Publication number: 20130230510Abstract: A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: December 4, 2012Publication date: September 5, 2013Applicants: University Health Network, CSL LimitedInventors: John Edgar Dick, Liqing Jin, Gino Luigi Vairo, David Paul Gearing, Samantha Jane Busfield
-
Publication number: 20110052574Abstract: A method for inhibition of leukemic stem cells expressing IL-3R?; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: December 4, 2008Publication date: March 3, 2011Inventors: John Edgar Dick, Liqing Jin, Gino Luigi Vairo, David Paul Gearing, Samantha Jane Busfield
-
Publication number: 20030004098Abstract: The present invention provides isolated DNA molecules encoding human and murine LIF and methods of producing LIF by the expression of the isolated DNA in suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.Type: ApplicationFiled: February 12, 2001Publication date: January 2, 2003Inventors: David Paul Gearing, Nicholas Martin Gough, Douglas James Hilton, Julie Ann King, Donald Metcalf, Edouard Collins Nice, Nicos Anthony Nicola, Richard John Simpson, Tracy Ann Willson
-
Patent number: 6395872Abstract: The invention features a method for identifying a cDNA nucleic acid encoding a mammalian protein having a signal sequence, which method includes the following steps: (a) providing library of mammalian cDNA; (b) ligating the library of mammalian cDNA to DNA encoding alkaline phosphatase lacking both a signal sequence and a membrane anchor sequence to form ligated DNA; 8 transforming bacterial cells with the ligated DNA to create a bacterial cell clone library; (d) isolating DNA comprising the mammalian cDNA from at least one clone in the bacterial cell clone library; (e) separately transfecting DNA isolated from clones in step (d) into mammalian cells which do not express alkaline phosphatase to create a mammalian cell clone library wherein each clone in the mammalian cell clone library corresponds to a clone in the bacterial cell clone library; (f) identifying a clone in the mammalian cell clone library which expresses alkaline phosphatase; (g) identifying the clone in the bacterial cell clone library correspType: GrantFiled: November 21, 2001Date of Patent: May 28, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventors: Sean Anthony McCarthy, David Paul Gearing, Douglas Adam Levinson
-
Patent number: 6391586Abstract: The invention features a method for identifying a cDNA nucleic acid encoding a mammalian protein having a signal sequence, which method includes the following steps: (a) providing library of mammalian cDNA; (b) ligating the library of mammalian cDNA to DNA encoding alkaline phosphatase lacking both a signal sequence and a membrane anchor sequence to form ligated DNA; (c) transforming bacterial cells with the ligated DNA to create a bacterial cell clone library; (d) isolating DNA comprising the mammalian cDNA from at least one clone in the bacterial cell clone library; (e) separately transfecting DNA isolated from clones in step (d) into mammalian cells which do not express alkaline phosphatase to create a mammalian cell clone library wherein each clone in the mammalian cell clone library corresponds to a clone in the bacterial cell clone library; (f) identifying a clone in the mammalian cell clone library which expresses alkaline phosphatase; (g) identifying the clone in the bacterial cell clone library correType: GrantFiled: November 7, 2000Date of Patent: May 21, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventors: Sean Anthony McCarthy, David Paul Gearing, Douglas Adam Levinson
-
Publication number: 20020045185Abstract: The invention features a method for identifying a cDNA nucleic acid encoding a mammalian protein having a signal sequence, which method includes the following steps:Type: ApplicationFiled: November 21, 2001Publication date: April 18, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventors: Sean Anthony McCarthy, David Paul Gearing, Douglas Adam Levinson
-
Patent number: 6261548Abstract: The present invention provides isolated DNA molecules encoding human and murine LIF and methods of producing LIF by the expression of the isolated DNA and suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.Type: GrantFiled: April 21, 1997Date of Patent: July 17, 2001Assignee: Amrad Corporation LimitedInventors: David Paul Gearing, Nicholas Martin Gough, Douglas James Hilton, Julie Ann King, Donald Metcalf, Edouard Collins Nice, Nicos Anthony Nicola, Richard John Simpson, Tracy Ann Willson
-
Patent number: 6136957Abstract: The invention provides a recombinant or synthetic receptor or a derivative thereof, for granulocyte-macrophage colony-stimulating factor (GM-CSF). The GM-CSF receptor is useful, inter alia, in the treatment or diagnosis of GM-CSF-related diseases, and in the screening of agonists and antagonists of GM-CSF receptors. The invention further provides antibodies directed against GM-CSF receptor or derivatives thereof, and pharmaceutical compositions comprising either the GM-CSF receptor, the receptor derivative, or an antibody thereto, and methods of using thereof.Type: GrantFiled: July 16, 1997Date of Patent: October 24, 2000Assignee: Amrad Corporation LimitedInventors: Nicos Anthony Nicola, Nicholas Martin Gough, David Paul Gearing, Donald Metcalf, Julie Ann King
-
Patent number: 6121045Abstract: The invention provides nucleic acid molecules which encode polypeptides having homology to proteins in the Delta family of proteins. The invention also provides vectors containing nucleic acid molecules of the invention and host cells containing the vectors.Type: GrantFiled: June 11, 1997Date of Patent: September 19, 2000Assignee: Millennium Biotherapeutics, Inc.Inventors: Sean Anthony McCarthy, David Paul Gearing
-
Patent number: 5952171Abstract: The invention features a method for identifying a cDNA nucleic acid encoding a mammalian protein having a signal sequence, which method includes the following steps: (a) providing library of mammalian cDNA; (b) ligating the library of mammalian cDNA to DNA encoding alkaline phosphatase lacking both a signal sequence and a membrane anchor sequence to form ligated DNA; (c) transforming bacterial cells with the ligated DNA to create a bacterial cell clone library; (d) isolating DNA comprising the mammalian cDNA from at least one clone in the bacterial cell clone library; (e) separately transfecting DNA isolated from clones in step (d) into mammalian cells which do not express alkaline phosphatase to create a mammalian cell clone library wherein each clone in the mammalian cell clone library corresponds to a clone in the bacterial cell clone library; (f) identifying a clone in the mammalian cell clone library which express alkaline phosphatase; (g) identifying the clone in the bacterial cell clone library correspType: GrantFiled: November 19, 1996Date of Patent: September 14, 1999Assignee: Millennium BioTherapeutics, Inc.Inventors: Sean Anthony McCarthy, David Paul Gearing, Douglas Adam Levinson
-
Patent number: 5750654Abstract: The present invention provides isolated DNA molecules encoding human and murine LIF, and methods of producing LIF by the expression of the isolated DNA in suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.Type: GrantFiled: March 29, 1995Date of Patent: May 12, 1998Assignee: Amrad Corporation LimitedInventors: David Paul Gearing, Nicholas Martin Gough, Douglas James Hilton, Julie Ann King, Donald Metcalf, Edouard Collins Nice, Nicos Anthony Nicola, Richard John Simpson, Tracy Ann Willson
-
Patent number: 5726036Abstract: The invention provides a recombinant or synthetic receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) and biochemical and/or biological equivalents, homologues, or derivatives thereof. The GM-CSF receptor is useful inter alia in treatment and diagnosis of GM-CSF related diseases, and in screening of agonists and antagonists of binding of GM-CSF to its cell-bound receptors. The invention further provides nucleic acid sequences encoding GM-CSF receptor, recombinant DNA molecules comprising these sequences, and transformed hosts carrying the recombinant DNA molecules, as well as antibodies directed against GM-CSF receptor, and pharmaceutical compositions comprising either the GM-CSF receptor or antibody thereto.Type: GrantFiled: February 7, 1995Date of Patent: March 10, 1998Assignee: Amrad Corporation LimitedInventors: Nicos Anthony Nicola, Nicholas Martin Gough, David Paul Gearing, Donald Metcalf, Julie Ann King